Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher due to the early success of its new all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program. The company reported a 336% increase in month-over-month sales for its TRT program since mid-December and a 54% reduction in customer acquisition costs. This $99-per-month program, delivered via telehealth, is expected to be Mangoceuticals’ primary growth driver.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model
Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher due to the early success of its new all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program. The company reported a 336% increase in month-over-month sales for its TRT program since mid-December and a 54% reduction in customer acquisition costs. This $99-per-month program, delivered via telehealth, is expected to be Mangoceuticals’ primary growth driver.